Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Income from Non-Controlling Interests (2016 - 2025)

Lexaria Bioscience's Income from Non-Controlling Interests history spans 10 years, with the latest figure at -$2496.0 for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests rose 14.78% year-over-year to -$2496.0; the TTM value through Nov 2025 reached -$9160.0, up 12.95%, while the annual FY2025 figure was -$9593.0, 27.92% up from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was -$2496.0 at Lexaria Bioscience, down from -$1390.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$1390.0 in Q3 2025 and bottomed at -$124573.0 in Q3 2021.
  • The 5-year median for Income from Non-Controlling Interests is -$9625.5 (2021), against an average of -$16620.1.
  • The largest annual shift saw Income from Non-Controlling Interests plummeted 270.62% in 2022 before it skyrocketed 81.63% in 2024.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$10325.0 in 2021, then decreased by 29.41% to -$13362.0 in 2022, then soared by 57.23% to -$5715.0 in 2023, then surged by 48.75% to -$2929.0 in 2024, then increased by 14.78% to -$2496.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Income from Non-Controlling Interests are -$2496.0 (Q4 2025), -$1390.0 (Q3 2025), and -$1514.0 (Q2 2025).